Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

2017 ◽  
Vol 57 (3) ◽  
pp. 345-354 ◽  
Author(s):  
Yves Horsmans ◽  
Jocelyn Zhou ◽  
Mateva Liudmila ◽  
George Golor ◽  
Oren Shibolet ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study

2017 ◽  
Vol 55 (01) ◽  
pp. 41-53 ◽  
Author(s):  
Kasra Shakeri-Nejad ◽  
Vassilios Aslanis ◽  
Uday Veldandi ◽  
Anne Gardin ◽  
Andreas Zaehringer ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group ◽  
Different Levels

scholarly journals Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

2019 ◽  
Vol 85 (9) ◽  
pp. 2011-2021 ◽  
Author(s):  
Niladri Chattopadhyay ◽  
Kai Riecke ◽  
Sandra Ligges ◽  
Torsten Zimmermann ◽  
Atef Halabi ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

2009 ◽  
Vol 31 ◽  
pp. 2459-2469 ◽  
Author(s):  
Ophelia Q.P. Yin ◽  
Neil Gallagher ◽  
Chiaki Tanaka ◽  
Deirdre Fisher ◽  
Venkat Sethuraman ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine

2013 ◽  
Vol 35 (6) ◽  
pp. 782-794 ◽  
Author(s):  
Susan Baird-Bellaire ◽  
Jessica A. Behrle ◽  
Vernon D. Parker ◽  
Alain Patat ◽  
Jeffrey Paul ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study

2021 ◽  
Author(s):  
Xinhui Chen ◽  
Xiaoming Cui ◽  
Nathalie Pognan ◽  
Michelle Quinlan ◽  
Shruti Kapoor ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

2013 ◽  
Vol 35 (3) ◽  
pp. 215-225 ◽  
Author(s):  
Jan Peveling-Oberhag ◽  
Stefan Zeuzem ◽  
Wei Peng Yong ◽  
Tiffany Kunz ◽  
Thierry Paquet ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

2015 ◽  
Vol 79 (6) ◽  
pp. 937-945 ◽  
Author(s):  
Zhanna Kobalava ◽  
Svetlana Villevalde ◽  
Yulia Kotovskaya ◽  
Holger Hinrichsen ◽  
Marc Petersen‐Sylla ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group
Sign in / Sign up

Export Citation Format

Share Document